| Literature DB >> 33615061 |
Ladan Golestaneh1, Angelo Karaboyas2, Kerri Cavanaugh3, Ebele M Umeukeje2, Tanya S Johns1, Roland J Thorpe4, Marino A Bruce5, Derek M Griffith6, Michal L Melamed1, Keith C Norris7.
Abstract
INTRODUCTION: Black men are over-represented in the end stage kidney disease population and are at disproportionate risk of unfavorable outcomes. There is a paucity of investigation to elucidate the mediators of this risk. This study attempts to identify residential community attributes as a possible contributor.Entities:
Keywords: Black men; community; health disparity; hemodialysis
Year: 2020 PMID: 33615061 PMCID: PMC7879205 DOI: 10.1016/j.ekir.2020.10.014
Source DB: PubMed Journal: Kidney Int Rep ISSN: 2468-0249
Characteristics of Black men in non-Black and Black residential communities
| Total = 702 | Percent Black residents <30% | Percent Black residents ≥30% | |
|---|---|---|---|
| Age, yr, mean (SD) | 58.5 (13.9) | 56.8 (14.4) | 0.12 |
| Vintage, yr, median (IQR) | 4.13 (1.74–7.01) | 3.85 (1.76–6.81) | 0.76 |
| Vascular access: AVF, | 238 (61.2) | 165 (52.7) | |
| Psychiatric illness yes, | 55 (14.1) | 38 (12.1) | 0.44 |
| Coronary artery disease ( | 137 (38.2) | 88 (28.2) | |
| Heart failure ( | 131 (36.6) | 112 (36.0) | 0.88 |
| Diabetes mellitus yes, | 211 (54.2) | 153 (48.9) | 0.16 |
| Hypertension ( | 300 (83.6) | 293 (93.9) | <0.001 |
| Charlson score ( | 5 (3–6) | 4 (3–5) | 0.002 |
| HTN as etiology of kidney disease, | 170 (43.7) | 157 (50.2) | 0.09 |
| BMI ( | 27.1 (23.3–31.7) | 26.5 (23.0–30.6) | 0.08 |
| Phosphorus (mg/dl) ( | 5.31 (1.52) | 5.39 (1.69) | 0.51 |
| Hemoglobin (g/l) ( | 116 (13) | 112 (12) | <0.001 |
| Albumin (mg/dl) ( | 3.91 (0.40) | 3.92 (0.42) | 0.65 |
| URR ( | 71.6 (7.5) | 71.2 (7.5) | 0.44 |
| Number of renal meds, median (IQR) ( | 3 (2–1)_ | 3 (2–3) | 0.41 |
| Prescriptions in past 4 months: | |||
| ESA, | 296 (78.1) | 241 (83.4) | 0.09 |
| Calcimimetic, | 128 (35.0) | 65 (25.2) | 0.01 |
| Phosphorus binders, | 327 (89.3) | 231 (88.5) | 0.74 |
| Dialysis minutes prescribed per wk, ( | 693.7 (96.5) | 657 (90.3) | <0.001 |
| Number of missed dialysis treatments per mo ( | |||
| 0 | 245 (88.1) | 227 (84.7) | 0.24 |
| ≥1 | 33 (11.9) | 41 (15.3) | |
| Number of shortened dialysis treatments (by ≥ 30 min) per mo ( | |||
| 0 | 250 (65.8) | 191 (61.2) | 0.21 |
| ≥1 | 130 (34.2) | 121 (38.8) | |
| Fluid removed (% dry weight) ( | 3.09 (1.50) | 3.15 (1.62) | 0.64 |
| Profit status: for-profit, | 344 (88.4) | 295 (94.2) | 0.007 |
| Facility size, median number patients (IQR) | 82 (64–110) | 65 (39–254) | 0.29 |
| Primary payer, | |||
| Medicare | 305 (78.4) | 234 (74.8) | |
| Medicaid | 18 (4.6) | 20 (6.4) | 0.44 |
| Other | 66 (17.0) | 59 (18.8) | |
| Rurality, %, median (IQR) | 8.85 (0–47.5) | 0 (0–62.2) | <0.001 |
| Poverty, %, median (IQR) | 11.8 (8.4–14.9) | 22.1 (17.7–22.5) | <0.001 |
| Household married, %, median (IQR) | 42.5 (37.2–49.7) | 36.0 (36.0–43.8) | <0.001 |
| Head of household: single female, %, median (IQR) | 11.7 (8.6–15.9) | 22.7 (15.6–23.8) | <0.001 |
| Household: 1 member bachelor’s degree or higher, %, median (IQR) | 29.6 (10.9–49.8) | 19.7 (13.6–30.5) | <0.001 |
| Household: active Internet, %, median (IQR) | 78.3 (77.6–83.4) | 67.9 (54.1–78.6) | <0.001 |
AVF, arteriovenous fistula; BMI, body mass index; DOPPS, Dialysis Outcomes and Practice Patterns Study; ESA, erythropoietin stimulating agent; HTN, hypertension; IQR, interquartile range; Rx, prescription; URR, urea reduction ratio.
Statistically significant values are in bold.
Figure 1The study cohort. ACS, American Community Survey; DOPPS, Dialysis Outcomes and Practice Patterns Study.
Association of racial composition of community of residence with hospitalization rate in Black men receiving hemodialysis
| Association of hospitalization rate and community racial composition in Black male patients (by race) during enrollment in DOPPS | Exposure variable as continuous with IRR for every 10% increase in % Black residents | |
|---|---|---|
| Unadjusted model | ||
| (IRR for hospitalization) | 1.05 (1.00–1.11) | 0.07 |
| + Age and vintage and DOPPS phase | 1.06 (1.00–1.12) | 0.07 |
| Model 1 + clinical variables (psychiatric illness, Charlson, CAD, DM, HTN, albumin, BMI, hemoglobin) | 1.07 (1.01–1.14) | 0.03 |
| Model 1+ dialysis provision (dialysis minutes per wk prescribed, URR, cinacalcet, AVF) | 1.05 (0.98–1.13) | 0.14 |
| Model 1 + patient behavior (substance use, shortened and missed treatments, | 1.05 (1.00–1.12) | 0.07 |
| Model 1 + Community/Facility characteristics (profit status, size, poverty, insurance, % married, higher education, Internet) | 1.05 (0.95–1.16) | 0.35 |
| Adjustment for all variables used in Models 1–5 (imputed data) | 1.09 (1.003–1.19) | 0.04 |
AVF, arteriovenous fistula; BMI, body mass index; CAD, coronary artery disease; DM, diabetes mellitus; DOPPS, Dialysis Outcomes and Practice Patterns Study; HTN, hypertension; IRR, incidence rate ratio; URR, urea reduction ratio.
Number of missed or shortened (by ≥30 minutes) per month.
Association of racial composition of community of residence with mortality in Black men receiving hemodialysis
| Association of mortality and community racial composition in Black male patients (by race) during enrollment in DOPPS | HR for death for every 10% in percent Black residents | |
|---|---|---|
| Unadjusted Model | 1.09 (1.01–1.17) | 0.02 |
| + Age and vintage and DOPPS phase | 1.10 (1.03–1.18) | 0.004 |
| Model 1 + clinical variables (psychiatric illness, Charlson, CAD, DM, HTN, albumin, BMI, hemoglobin) | 1.14 (1.04–1.24) | 0.004 |
| Model 1+ dialysis provision (dialysis minutes per wk prescribed, URR, cinacalcet, AVF) | 1.11 (1.03–1.19) | 0.005 |
| Model 1 + patient behavior (substance use, shortened and missed treatments, fluid removed) | 1.09 (1.02–1.18) | 0.02 |
| Model 1 + community/facility characteristics (profit status, size, poverty, insurance, % married, higher education, Internet) | 1.26 (1.04–1.53) | 0.02 |
| Adjustment for all variables used in Models 1–5 (imputed data) | 1.29 (1.05–1.59) | 0.02 |
AVF, arteriovenous fistula; AVG, arteriovenous graft; BMI, body mass index; DOPPS, Dialysis Outcomes and Practice Patterns Study; DOPPS Phase, DOPPS 2010–2015; ESA, erythropoietin stimulating agent; HR, hazard ratio; HTN, hypertension; IRR, incidence rate ratio; Rx, prescription; URR, urea reduction ratio.